NEW YORK, July 4, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Covidien plc (NYSE: COV), Hospira Inc. (NYSE: HSP), Insmed Incorporated (NASDAQ: INSM), and Thoratec Corporation (NASDAQ: THOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Boston Scientific Corporation Research Report
On June 28, 2013, Boston Scientific Corporation (Boston Scientific) announced that it has entered into a definitive agreement to acquire Bard EP, the electrophysiology (EP) business of C. R. Bard, Inc., for $275 million in cash. According to the Company, the transaction supports its strategy to provide a robust portfolio of solutions for cardiac catheter ablations and other EP tools to diagnose and treat a variety of conditions in which the heart beats abnormally. Further, Boston Scientific stated that Bard EP's strong commercial team and complementary portfolio (including catheter and recording device technologies) would enable it to better serve the rapidly growing global EP market with a stronger and more comprehensive offering. Boston Scientific expects to close the transaction in the second half of 2013, subject to customary closing conditions. Upon closing of this transaction, Bard EP would become part of the existing Boston Scientific EP business within the Company's Rhythm Management unit. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5649_BSX]
Covidien plc Research Report
On July 1, 2013, Covidien plc (Covidien) announced that it has completed the separation of its Pharmaceuticals business. A new independent company, Mallinckrodt plc (Mallinckrodt), now holds this spin-off business. According to Covidien, the spin-off enables both businesses to pursue their own strategic and operational plans, including setting optimal levels of investment in research and development and creating business-appropriate capital structures. José E. Almeida, Covidien Chairman, President and Chief Executive Officer, said, "Covidien is well positioned to deliver on its strategic initiatives, including broadening innovation focus, aggressively managing its portfolio, capitalizing on emerging markets opportunities and optimizing spending to provide for investments in innovation and growth." "We are maintaining our long-term financial goals and continue to target top-line growth at or above the markets in which we compete." The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/a748_COV]
Hospira Inc. Research Report
On June 28, 2013, Hospira Inc. (Hospira) reported that it has received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the European Commission (EC) approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease, and plaque psoriasis. According to Hospira, Inflectra is a biosimilar medicine to the reference medicinal product, Remicade (infliximab), and is the first monoclonal antibody therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1b4f_HSP]
Insmed Incorporated Research Report
On July 1, 2013, Insmed Incorporated (Insmed) announced positive developments in both of its clinical development programs for ARIKACE or liposomal amikacin for inhalation (LAI). Insmed reported that its Phase 3 study of once-daily ARIKACE to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients conducted at 70 sites in Europe and Canada met its primary endpoint of non-inferiority compared with twice-daily TOBI (tobramycin inhalation solution) for relative change in forced expiratory volume in one second (FEV1), measured at the end of the third treatment cycle (24 weeks) as compared to baseline. Further, Insmed also revealed that the US Food and Drug Administration (FDA) has designated ARIKACE as a Qualified Infectious Disease Product (QIDP) for the treatment of Non-Tuberculous Mycobacteria (NTM) lung infections. ARIKACE was also granted Fast Track designation by the FDA for the treatment of NTM. The Full Research Report on Insmed Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9955_INSM]
Thoratec Corporation Research Report
On July 1, 2013, Thoratec Corporation (Thoratec) reported that it has acquired the DuraHeart II (DH-II) ventricular assist system from Terumo Corporation (Terumo) for an upfront cash payment of $13 million, as well as potential future milestone payments, based on regulatory approvals and product sales, of up to $43.5 million. Under the agreement, a team of Terumo employees will also transition to Thoratec and will continue to be based in Ann Arbor, Michigan. In addition, the two Companies have entered into a distribution partnership, in which Terumo will commercialize DH-II in Japan and potentially other parts of Asia. According to Thoratec, it intends to apply its resources and expertise in mechanical circulatory support in order to advance the DH-II program through product development and clinical trials. Thoratec expects a first-in-human implant of the DH-II pump in 2016 to be followed by clinical trials in the US and abroad. After the clinical trials, Thoratec stated that its distribution partnership with Terumo should optimize patient access to the DH-II technology on a worldwide basis. Thoratec expects that the acquisition will add incremental ongoing operating expenses, primarily related to research and development, of approximately $6 million to $7 million in the second half of 2013. The Full Research Report on Thoratec Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/18e4_THOR]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports